AI Robotics in Medicine

Simply Wall Street’s AI healthcare screener highlights Pfizer, Medtronic, and Hinge Health as meaningful AI plays across drug R&D, surgical robotics/video, and digital musculoskeletal care. The picks span very different scales—Pfizer about $61.

9b in revenue, Medtronic roughly $36. 4b, and Hinge about $646.

3m in software—showing AI deployed from biomolecular modeling and the Hugo system to motion tracking plus a nerve‑stimulation wearable and clinical support.

Risks to watch: Pfizer’s dividend isn’t fully covered by earnings or free cash flow, and Medtronic faces margin pressure, underperforming diabetes and surgical units, and a complex Diabetes spin‑off. Source: Simply Wall Street.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

Geography: United States, European Union, United Kingdom, Canada, Israel, China, Japan, South Korea, India, Singapore, Australia, United Arab Emirates, Saudi Arabia

1. Simply Wall Street flags Pfizer, Medtronic, Hinge as AI healthcare plays

Simply Wall Street’s Transformative AI Healthcare Stocks screener spotlights Pfizer, Medtronic, and Hinge Health as companies with meaningful AI exposure. Pfizer reports about $61.

9b in annual revenue across geographies, while Medtronic generates roughly $36. 4b led by cardiovascular and neuroscience segments.

Hinge Health, focused on digital musculoskeletal care, reports about $646. 3m in software revenue.

The note cites Pfizer’s AI-powered R&D partnerships spanning drug discovery and biomolecular modeling, and Medtronic’s push into AI-guided surgical video and robotics via its Hugo system.

It also flags Hinge’s platform combining AI motion tracking, a nerve-stimulation wearable, and clinical support.

Risks include Pfizer’s dividend not fully covered by earnings or free cash flow, and Medtronic’s margin pressure, underperforming diabetes and surgical units, and a complex Diabetes spin-off.

Key facts:

- Pfizer annual revenue about $61.9b; $37.4b U.S., $9.4b emerging, $16.4b other developed.

- Pfizer dividend not fully covered by earnings or free cash flow.

- Medtronic revenue about $36.4b; Cardiovascular $14.0b, Neuroscience $10.3b, Medical Surgical $8.8b.

- Medtronic dividend yield 3.41%.

- Medtronic pushing AI-guided surgical video and Hugo robotic system.

Why it matters: The picks span pharma, medtech, and digital health, offering diversified ways to gain AI exposure in care delivery and R&D.

Investors get different risk-reward profiles: Pfizer with scale and AI partnerships but a stressed dividend, Medtronic with AI surgery and robotics ambitions amid restructuring, and Hinge with a software-first MSK model.

What to watch: execution on Medtronic’s robotics and Diabetes spin-off, Pfizer’s cash flow versus payout and late-stage pipeline progress, and Hinge’s ability to sustain employer and plan adoption at scale.

Simplywall